A sweeping analysis of blood metabolites from nearly a quarter of a million Britons has uncovered that when your biological age outstrips your chronological one, the risk of several forms of dementia climbs significantly. The research, leveraging the UK Biobank’s vast repository, also reveals a striking combined threat: individuals with both accelerated metabolic aging and a high-risk genetic profile faced a tenfold greater likelihood of developing dementia compared to those free of these burdens.
Measuring Biological Age from a Blood Sample
Rather than counting birthdays, scientists from the United Kingdom turned to a tool called the MileAge clock. This algorithm estimates biological age from metabolites – small molecules circulating in blood that reflect the body’s internal state. Using nuclear magnetic resonance spectroscopy, the team measured a broad panel of metabolites in plasma samples. By subtracting a person’s chronological age from their MileAge-predicted biological age, they arrived at a delta score. A positive delta meant someone was metabolically older than their years would suggest. Machine learning helped refine these age predictions, building on prior work that already tied the MileAge clock to overall health and longevity.
What the Data Revealed
The study started with 274,315 UK Biobank participants who had metabolite measurements. After excluding individuals with pre-existing dementia, pregnancy, and incomplete data, the final group numbered 223,496 people. Over a median follow-up of 13.7 years, 3,976 participants developed dementia – 1,881 Alzheimer’s disease, 933 vascular dementia, and the remainder other or unspecified subtypes.
A higher MileAge delta, marking accelerated biological aging, was clearly linked to an elevated chance of vascular dementia, unspecified dementia, and all-cause dementia. For all dementia types combined, the hazard ratio (HR) stood at 1.20 after accounting for age and sex. Adjustments for education, marital status, income, socioeconomic deprivation, and APOE genotype barely moved these figures. The strongest signal emerged for vascular dementia, with an HR of 1.61. Intriguingly, no statistically significant association surfaced for Alzheimer’s disease risk itself. However, a high delta did forecast an earlier onset across every subtype, Alzheimer’s included. On average, participants developed Alzheimer’s at 75.6 years, but those racing ahead on the metabolic clock saw the disease strike sooner.
The Story Told by Individual Metabolites
Zooming in on specific molecular players painted a more detailed portrait. The branched-chain amino acids leucine and valine, together with the total pool of these amino acids, correlated with a lower risk of Alzheimer’s disease. A series of lipoprotein measures also appeared protective. For vascular dementia, 72 metabolites showed associations, but only one – GlycA, a composite biomarker of systemic inflammation – was tied to heightened risk; lipids and lipoproteins largely pointed in the opposite, protective direction.
Patterns varied by dementia type. Fifty-four metabolites were linked to dementia attributed to other diseases, while 43 related to unspecified dementia, and a broad set of 106 metabolites associated with all-cause dementia. Notably, a glucose-lactate composite score, which partially captures pre-analytical glycolysis between blood draw and sample processing, emerged as a risk factor for both unspecified and all-cause dementia. Reassuringly, amino acids like leucine and valine, along with several lipid measures, again showed inverse relationships with overall dementia risk.
When Genetic Risk Meets Accelerated Aging
One of the most sobering findings centred on the interplay between biological aging and the APOE ε4 allele, the strongest genetic risk factor for late-onset Alzheimer’s. Participants carrying two copies of ε4 – meaning high genetic predisposition – who also displayed pronounced metabolic aging had a tenfold increase in all-cause dementia risk compared to individuals with neither the high-risk genotype nor an elevated MileAge delta. Statistical modelling suggested the two influences operate largely independently, piling risk on top of risk rather than interacting synergistically.
A Path Toward Earlier Warnings
The study reinforces the notion that dementia is not an inevitable companion of growing old. An estimated 45% of cases may be delayed or prevented through risk factor modification, especially when action starts early. Metabolic clocks like MileAge could one day help flag those whose biology is rushing ahead, well before memory falters. Since the clock captures signals from systemic inflammation, lipid metabolism, and amino acid balance, it offers a multidimensional snapshot that might complement genetic tests and clinical assessments. The findings, while derived from a predominantly white British cohort, underscore the promise of metabolite-based biomarkers for early risk stratification and highlight that the pace of internal aging matters at least as much as the years on the calendar.
Publication date: 2026.05.22
Source: Mutz J. et al. Metabolomic ageing (MileAge) in mid-life predicts incident vascular, unspecified and all-cause dementia. Alzheimers Dement. 2026 May;22(5):e71280. doi: 10.1002/alz.71280. PMID: 42126002; PMCID: PMC13169133. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71280